LATS1 Polyclonal Antibody
Sizes: 60μL, 120μL, 200μL
Catalogue Numbers: E-AB-93222-60, E-AB-93222-120, E-AB-93222-200
Citations, Manuals and MSDS Available upon request.
Abbreviation: LATS1
Target Synonym: LATS1; WARTS; wts
Research Areas: Cancer, Cell Biology
Conjugation: Unconjugated
Host: Rabbit
Species Reactivity: Human, Mouse, Rat
Application: WB, IHC
Isotype: IgG
Clonality: Polyclonal
UNIProt ID: O95835
Background: The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
Concentration: 1mg/mL
Immunogen: A synthetic peptide of human LATS1
Buffer: PBS with 0.01% thiomersal, 50% glycerol, pH7.3.
Purification Method: Affinity purification
Dilution: WB 1:500-1:2000, IHC 1:50-1:200
Calculated MW: 76kDa/126kDa
Observed MW: 150KDa
Storage: -20°C/One year. Avoid freeze / thaw cycles.
Shipping: Ice bag
Research Use Only